Summary: Researchers achieved a major breakthrough by reversing structural brain abnormalities and behavioral deficits associated with autism spectrum disorder (ASD). The research group identified a prominent structural defect within the “axon initial segment” (AIS)—the critical root region of a neuron where electrical action potentials are generated.
Utilizing a sophisticated chemogenetic intervention in an established ASD mouse model, investigators successfully restored these shortened neural components to normal lengths, driving a recovery in sociability and a marked reduction in repetitive behaviors.
Key Facts
- The Axon Initial Segment Defect: Researchers identified prominent structural abnormalities in the axon initial segment (AIS), the precise region at the root of a neuron responsible for generating the electrical signals (action potentials) that drive brain communication.
- The Social Circuit Bottleneck: In the neural circuit projecting from the prefrontal cortex (a region vital for social behavior) to the dorsal raphe nucleus, the AIS was found to be abnormally shortened, resulting in a significantly reduced neuronal firing capacity.
- The 15q Dup Genetic Model: The discovery was made by analyzing an ASD mouse model (15q dup mice) that carries the exact genetic duplications closely associated with human autism spectrum disorder.
- Chemogenetic Engineering (DREADD): To test whether these profound physical deformities were permanent, the team deployed an advanced chemogenetic technique known as DREADD to artificially and selectively activate the damaged prefrontal cortex-to-dorsal raphe nucleus pathway.
- Reversal of Structural Damage: Targeted chemogenetic activation successfully recovered the shortened length of the axon initial segment, restoring it to a completely normal biological level.
- Rescue of Behavioral Metrics: Accompanying this physical repair was a clear improvement in the mice’s autism-like behaviors, including a rescue of native sociability and a severe reduction in compulsive, repetitive behaviors.
- A New Therapeutic Foundation: Co-led by Professor Masashi Fujitani and Assistant Professor Yoshinori Otani, the study establishes that impaired neural plasticity in ASD is completely reversible, offering a solid template for entirely new circuit-based therapeutic strategies in humans.
Source: Shimane University
Autism spectrum disorder (ASD) is an innate brain developmental disorder that often manifests from early childhood. While genetic factors and differences in brain development are known to be involved, a definitive cure has yet to be established. Understanding and potentially reversing the underlying neurological abnormalities is a major challenge in neuroscience.
This feat has now been made possible by a collaborative research group led by Prof. Masashi Fujitani and Assistant Prof. Yoshinori Otani from the Department of Anatomy and Neuroscience, Faculty of Medicine, Shimane University, Japan, along with Prof. Toru Takumi from Kobe University and Associate Prof. Kohei Koga from Hyogo Medical University.
In a study published in the renowned journal Cell Death & Disease on May 19, 2026, the team analyzed an ASD mouse model (15q dup mice) carrying genetic duplications associated with human ASD.
The researchers discovered prominent abnormalities in the “axon initial segment” (AIS)—a critical region at the root of a neuron where electrical signals (action potentials) are generated.
Specifically, in the neural circuit projecting from the prefrontal cortex (a region vital for social behavior) to the dorsal raphe nucleus, the AIS was abnormally shortened, resulting in reduced neuronal excitability (firing capacity).
“Given that we observed significant structural abnormalities in the axon initial segment of the ASD mouse model, we sought to understand if these changes were reversible,” explains Prof. Fujitani.
“To investigate this, we utilized a chemogenetic technique known as DREADD, which enabled us to artificially and selectively activate the specific neural circuit projecting from the prefrontal cortex to the dorsal raphe nucleus.”
The results of this study showed that targeted chemogenetic activation successfully recovered the shortened length of the axon initial segment to its normal level. Accompanying this structural restoration was a marked improvement in the mice’s ASD-like behavioral abnormalities, including a recovery in sociability and a reduction in repetitive behaviors.
To Prof. Fujitani and the research group, these results signify a major milestone.
“Our study demonstrates that the structural brain abnormalities and impaired AIS plasticity observed in ASD animal models are not irreversible damage, but rather a reversible and recoverable phenomenon,” comments Prof. Fujitani.
“The evidence that behavioral abnormalities can be rescued by intervening in specific neural circuits provides a solid foundation for entirely new therapeutic strategies for autism spectrum disorder in the future.”
Key Questions Answered:
A: The axon initial segment (AIS) is the physical launchpad at the root of a neuron where all electrical signals are generated. The collaborative Japanese study revealed that in autism models, this segment is abnormally short, acting like a pinched wire that prevents social brain regions from firing electrical messages effectively.
A: By using an advanced engineering technique called DREADD. This chemogenetic tool allowed scientists to pass a specific chemical signal through the prefrontal cortex pathway, artificially activating the circuit and prompting the shortened axon segments to physically grow back to their normal lengths.
A: It proves that the neurological abnormalities underlying autism are not permanent, irreversible damage. By showing that altering a specific neural circuit can physically rebuild brain architecture and eliminate behavioral deficits, the study builds a rock-solid foundation for entirely new, circuit-targeted therapies.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Autism research news
Author: Shuko Imawaka
Source: Shimane University
Contact: Shuko Imawaka – Shimane University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Restoration of axon initial segment plasticity via chemogenetic activation rescues autism-related behaviors” by Yoshinori Otani, Xiaowei Zhu, Xinlang Liu, Kohei Koga, Ryo Kawabata, Hisao Miyajima, Toru Takumi & Masashi Fujitani. Cell Death and Disease
DOI:10.1038/s41419-026-08873-0
Abstract
Restoration of axon initial segment plasticity via chemogenetic activation rescues autism-related behaviors
Autism spectrum disorder (ASD) presents a major clinical challenge, necessitating the identification of novel therapeutic targets rooted in its underlying pathophysiology. The axon initial segment (AIS) is the critical site for action potential initiation and a hub for homeostatic plasticity; however, its involvement in ASD remains poorly defined.
Herein, we report significant structural and functional deficits in the AIS within a clinically relevant ASD mouse model harboring a 15q11-13 duplication (15q dup).
We observed that pyramidal neurons in the medial prefrontal cortex (mPFC) exhibited shortened AIS, resulting in reduced neuronal excitability and impaired plasticity. Importantly, these abnormalities were specific to long-range circuits, including the mPFC–dorsal raphe nucleus (DRN) pathway, which is critical for social behavior.
We employed a circuit-specific chemogenetic strategy that activates these mPFC–DRN projection neurons to test the reversibility of this phenotype. Remarkably, this targeted intervention normalized AIS structure and rescued core ASD-like behaviors, including social interaction deficits and repetitive behaviors.
These results demonstrated that AIS alterations in this ASD model represent a reversible form of maladaptive plasticity, rather than permanent neuropathology.
Our study highlights circuit-specific AIS modulation as a promising novel avenue for therapeutic interventions aimed at correcting fundamental neuronal excitability deficits in ASD.
